• ERT and Bioclinica are now Clario. Find out more about our new name, and why we have come together.

Your using an unsupported browser. Please update to a modern browser for a better experience.

Optimize your trial data with Clario’s eCOA Science Team

Our highly-respected and experienced Science Team works with Clients across all therapeutic areas to deliver the regulatory-compliant eCOA data they need.

Involving our Science Team early in a study’s lifecycle is vital to minimizing the risk of poor-quality data or unnecessary patient burden. They will advise on the most appropriate outcome assessments and methodologies to deliver your critical eCOA data.

Delivering value throughout the study lifecycle

1. COA Endpoint Strategy Consultation
  • Early stage support to guide your Clinical Development Program:
    • Gap analysis and instrument identification
    • Conceptual model development
    • Endpoint model development
  • Scientific dissemination
2. Protocol Development
  • Protocol review and recommendations for:
    • Assessments
    • Endpoints
    • Patient and site considerations
    • Patient population
    • Patient safety
    • eDiary design
  • Relationships with copyright holders
3. Study Design
  • Recommendations on:
    • Modality selection & deployment
    • Regulatory compliance
    • Strategies for enhanced patient engagement, retention and compliance
    • Therapeutic area best practices and lessons learned
4. Study Start-Up & Conduct
  • Patient, site and rater training
  • Selection of investigator notifications
  • Data monitoring & study oversight
5. Close Out
  • Review of study outcomes and results
  • Rapid database lock
  • Guidance on next development phase/lifecycle opportunities

Our Regulatory Specialists are on hand throughout the lifecycle of a study, offering support with communications, Health Authority and IRB/EC submissions, briefing books and evidence dossiers.

eCOA technology solutions built around the patient

Clario’s eCOA brings the trial to your patient, enabling sponsors to deliver at-site, hybrid, and virtual clinical trials. Our aim is to make participation both convenient and safe while ensuring data remains high-quality and regulatory-compliant. Decentralize your trial with confidence using Clario eCOA.

  • At-home site assessments with eCOA Live
  • Patient engagement & retention strategies
  • Patient choice: how and where to take part including BYOD or provisioned devices
  • At-home photo + ePRO capture on a single device with eCOA Multimedia
  • Integration with connected devices including wearables, sensor and digital biomarkers
  • Remote visit support
eCOA Live with Virtual Video Visit

​​Why Clario eCOA?

Clario is committed to generating the high-quality evidence you need to better evaluate the safety and efficacy of your compounds and ultimately transform patients’ lives. Here’s how:

Global leader in hybrid and decentralized trials with over 25 years of experience

Clario has been guiding patients in remote data collection since 2005. Our innovative range of virtual, hybrid and remote eCOA solutions enables sponsors to offer patients a convenient and safe way to take part in clinical research while maintaining the high-quality data you need.

Scientific approach for data-driven decisions

Clario’s Science Team advises on the most appropriate eCOA solution and is on hand throughout your study to ensure your trial generates high-quality, regulatory-compliant data and evidence. Advanced, real-time reporting gives sponsors and sites visibility into how their trial and patients are progressing.

Patient choice through flexible technology solutions

Whether your trial is taking place at a site, at home, remotely, or a combination of these, Clario will tailor its technology and services to best suit your study. We will ensure that the devices selected are appropriate for your patient population and geographical requirements. Contact us to learn more about our BYOD solution.

Innovation and industry collaboration

Clario introduced the first eDiary back in 1996 and continues to drive innovation within the industry to advance medical research:

  • ePRO Consortium: founding member, including BYOD Working Group
  • Mobilise-D: supporting the development of the first clinically-validated mobility endpoint

Global delivery, at scale

Clario ships over 90,000 devices every year to over 110 countries. Our global logistics expertise and advanced ePRO clinical trial outcome assessment software ensure that your trials run smoothly and on time.

Regulatory guidance

Clario’s Science Team will advise on regulatory requirements for your individual study to ensure it meets FDA, EMA or other global regulatory agency requirements.






eCOA Studies



Clario’s therapeutic area expertise

With experience across all therapeutic areas and 560 indications, Clario’s team of scientific experts is here to advise you on regulatory requirements and best practices when implementing electronic Clinical Outcome Assessments.

Download our exclusive therapeutic area Best Practices Guides to learn how to set your trial up for success.

Oncology best practice guide

Pain best practice guide

Schizophrenia best practice guide

Migraine best practice guide

Diabetes best practice guide

Suicide Ideation and Behavior

Infectious diseases

eCOA Science Team

eCOA and DCT Key Opinion Leaders

Bryan McDowell headshot

Bryan McDowell, MSc, MBA

VP eCOA Clinical Science & Consulting

Valdo Arnera headshot

Valdo Arnera, MD 

General Manager & Scientific Advisor

New to eCOA?

What is eCOA?

Electronic Clinical Outcome Assessments, or eCOA for clinical trials, measure how patients feel or function during clinical trials. By capturing clinical data electronically, you can be confident that your patient’s data is high-quality and regulatory-compliant. Put simply, eCOA avoids the quality and time issues associated with paper diaries, such as illegible answers, transcription errors and inconsistent or conflicting data. Also, the FDA recommends ePRO.

eCOA comes in many forms:

  • ePRO: Patient Reported Outcomes. Patients report on their health via questionnaires or assessments. Examples include quality of life or activity outcomes.
  • eClinRO: Clinician Reported Outcomes. Health outcomes are reported by a clinician. An example may include a physical examination such as PASI.
  • eObsRO: Observer Reported Outcomes. Completed by someone other than the patient or the clinician, such as a caregiver, based on events and behaviors observed.
  • ePerfO: Performance Outcomes are measures from specific tasks the patient is asked to perform. An example might be performing a timed task.

eCOA for clinical trials can be easily integrated with connected devices, wearables or sensors to generate additional evidence in support of your clinical trial.

eCOA Frequently Asked Questions

Paper COA is much less reliable than electronic data capture. Paper-based PROs, for example, do not control when data entries are made (e.g., all in one go before a site visit, or forward-filled with made-up answers), or whether patients have completed the entire assessment or not. In fact, recent research showed that 45% of patients in a pain study invented data by forward filling at least once.1 Although paper compliance can seem high, back and forward filling can actually make true compliance very low.

Handwritten entries may also be illegible or the answers might simply not make sense, all contributing to poor quality and unreliable data. By comparison, electronic COA (eCOA) delivers accurate, time-stamped, high-quality, compliant data every time.

 1. “Patient Non-compliance with Paper Diaries,” Stone, A., British Medical Journal, 2002

To receive high-quality, accurate data, it is critical to use eCOA in the following instances:

  • When patients need to fill in a daily diary or assessment
  • When the data that is captured supports a primary endpoint
  • When monitoring treatment-related suicidal ideation and behavior (SIB)
  • When integrating data with another data source

To reduce the data burden and receive consistent, high-quality data, we recommend using eCOA in the following scenarios:

  • During oncology trials, to support the treatment’s efficacy with additional PRO information
  • In large-scale studies, e.g., across diverse populations and in multiple countries
  • For assessments that require complex calculations or scoring

Take a look at the FAQ above about when it’s critical or recommended to use eCOA. It’s also important to remember that eCOA delivers higher-quality data and more accurate results than paper data collection, avoiding, for example, transcription errors and inconsistent or conflicting data. eCOA enables real-time insights into patient safety and study performance, which is critical for sponsors. Check out this infographic for a comparison between paper and eCOA.

Take a look at our Guide to implementing eCOA in clinical trials. And why not talk to our Science Team who are on hand to answer your questions about how to move forward with ePRO.

With the acceleration of decentralized trials, patients are now more responsible than ever for collecting their data, making sure they capture it at the right time and that it’s high quality. eCOA is the ideal solution. Why is that? eCOA makes trials simple to take part in, fitting in with patients’ daily lives and other family or work commitments:

  • Clario’s eCOA decentralizes trials. For patients this means fewer site visits, saving them time and making it much more convenient and simple to take part in a study
  • Patients can also carry on seeing their clinician ‘face-to-face’ with Clario’s Virtual Video Visits
  • It’s easy to collect multiple endpoints. Clario’s eCOA integrates with any connected device such as our at home PEF, blood glucose monitor or heart rate monitor
  • Patients receive automatic reminders to complete their diary entries to help avoid missed diary entries
  • Motivational and educational messaging encourages continued participation in the trial
  • Patients can even take photos at home rather than having to travel to site, within the eCOA assessment, with eCOA Multimedia

eCOA increases patient engagement in five ways:

  • Clario’s virtual eCOA solutions enable patients to complete clinical outcome assessments at home, minimizing the need to travel to site and therefore fitting better into patients’ daily lives
  • eCOA also provides the patient with the choice of using the technology that suits them best – whether this is their own device (BYOD) or a provisioned device, via the web or at a site
  • eCOA captures assessments simply and quickly with automatic branching logic. Assessments are then automatically transferred to the study database. The burden placed on the patient is therefore greatly reduced when compared to using paper diaries
  • When additional endpoints need collecting, Clario’s eCOA easily integrates with other connected devices. Data is automatically transferred to the eCOA device, making the process much simpler than having two unconnected devices or having to manually transcribe readings
  • eCOA sends out automatic diary reminders, motivational messaging and education to patients around their trial participation and condition

There is mounting evidence in the literature that supports equivalency of PRO measures between paper and electronic modes, and across different devices. This evidence includes two quantitative meta-analyses, which concluded that the mode of PRO administration (paper vs. electronic) does not impact measurement equivalence.7,8 Qualitative syntheses of cognitive debrief and usability studies and expert screen review studies further conclude comparability of PRO assessments when migrating from paper to electronic and across electronic devices as long as eCOA best practices are followed.9,10

7. Gwaltney CJ et al. Value Health 2008;11: 322-333.
8. Muehlhausen W et al. Health Qual Life Outcomes 2015;13:167-187.
9. Muehlhausen W et al. Value Health 2018;21:41-48.
10. Dumais KD et al. ISPOR 2021, accepted abstract.

eCOA meets the recommended regulatory guidelines for collecting and reporting data as required by the protocol while ensuring data quality. This includes ALCOA standards. ALCOA requires data to be Attributable (i.e., can it be traced back to the patient?), Legible, Contemporaneous (i.e., is the entry filled out at the right time?), Original (is it the first place the data is recorded?) and Accurate. Because eCOA meets these quality requirements, regulators’ questions about patient-entered data are minimized.

Paper-based collection methods (e.g., paper diaries) may not meet global regulatory standards.

Although at face value it may appear that eCOA is more expensive than paper, there are many hidden, often substantial costs when using paper data collection. For example, labor costs for data transcription and validation, increased variability, and missing data leads to more patients and longer study durations than with eCOA. However, the much bigger issue is the cost to the trial of having inaccurate, poor-quality data as a result of paper diaries, which may negatively impact the outcome of the trial itself.

Manual data entry, data corrections and incomplete or incomprehensible data in paper-based collection can easily outweigh the cost of using eCOA. With eCOA, these challenges, and therefore their associated costs, are minimized. In addition, paper does not enable sites or sponsors to review data in real time. Clario’s eCOA, through its Trial Oversight solution, enables sites and sponsors to identify potential issues early, such as low complying patients. This visibility empowers sites and sponsors to make adjustments or offer additional support to ensure the trial stays on track and on budget.

By enabling patients to bring-their-own-device (BYOD), study costs can be reduced significantly.

A number of studies have shown that eCOA is preferred across indications.2-6

2. Khurana et al., State of BYOD: Lessons in Acceptability and Compliance from 30 Trials. Poster presented at Virtual ISPOR 2021.
3. Ryan et al. 2002. A comparison of an electronic version of the SF-36 General Health Questionnaire to the standard paper version. Qual Life Res;11(1):19-26
4. Ring A, et al. 2008. A Randomized Study of Electronic Diary versus Paper and Pencil Collection of Patient-Reported Outcomes in Patients with Non-Small Cell Lung Cancer. Patient; 1:105-113. 10.
5. Tsang LC, et al. 2001. Patient preferences for using technology to track and self-manage diabetes. Journal of Telemedicine and Telecare; 7:47-50 11.
6. Allena M, et al. 2012. An electronic diary on a palm device for headache monitoring: a preliminary experience J Headache Pain; 13:537-541.

The assumption is that elderly patients will have a low compliance level to protocol requirements and/or completing unsupervised self assessments. Common concerns include impaired vision, comprehension or dexterity; forgetfulness; lack of computer experience; and fear of something that isn’t familiar.

However, results show that patients aged 60+ have the same compliance rate, if not better, than younger participants. Clario eCOA keeps assessments simple, provides reminders and pop-up help, uses larger fonts and target areas and provides appropriate user training.

Talk to a specialist

Our team of experts is available to address questions you may have about eCOA. Submit your contact information and we’ll be in touch shortly.